The Nomination Committee of CellaVision AB (publ) (”CellaVision” or the ”Company”) hereby announces the Nomination Committee’s proposals to the Annual General Meeting (the ”AGM”) regarding the number of Board members, election of Board members, election of the Chairman of the Board, and Board remuneration. In brief, the Nomination Committee’s proposal entails re-election of Mikael Worning, Christer Fåhraeus, Stefan Wolf, Ann-Charlotte Jarleryd and Emil Hjalmarsson, and new election of Zlatko Rihter, as Board members. It is further proposed that Zlatko Rihter be elected as new Chairman of the Board. Louise Armstrong-Denby has declined re-election.

CellaVision published, on 25 March 2026, the notice convening the AGM to be held on 28 April 2026. The notice stated that the Nomination Committee’s work regarding proposals for the number of Board members, election of Board members, election of Chairman of the Board, and Board remuneration (items 12–15 on the agenda of the notice) was ongoing. The Nomination Committee hereby announces that its proposals in these respects are complete. The Nomination Committee, which has consisted of Nicklas Hansen, appointed by William Demant Invest A/S, Joel Eklund (Chairman of the Nomination Committee), appointed by Grenlunden CEVI AB, Erik Ståhl Hallengren, appointed by SEB Funds and Christer Fåhraeus, appointed by Christer Fåhraeus and companies, proposes the AGM to resolve: that the Board of Directors shall consist of six Board members and no deputy Board members;that remuneration to the Board shall be SEK 755,000 (previously SEK 755,000) to the Chairman of the Board and SEK 280,000 (previously SEK 280,000) each to the other Board members, however, that no remuneration shall be paid to Board members who are employed by the Company, additional remuneration shall be SEK 100,000 (previously SEK 100,000) to the Chairman of the Board’s Audit Committee and SEK 50,000 (previously SEK 50,000) to the other members of the Audit Committee, and SEK 50,000 (previously SEK 50,000) to the Chairman of the Board’s Remuneration Committee, and SEK 25,000 (previously SEK 25,000) to the other members of the Board’s Remuneration Committee;that Mikael Worning, Christer Fåhraeus, Stefan Wolf, Ann-Charlotte Jarleryd and Emil Hjalmarsson be re-elected as Board members, and that Zlatko Rihter is elected as new Board member for the period until the end of the next AGM. Louise Armstrong-Denby has declined re-election; andthat Zlatko Rihter be elected as new Chairman of the Board. Mikael Worning has declined re-election as Chairman of the Board, but is available to serve as a Board member. Information regarding the proposed new Board member Zlatko Rihter (born 1970) is proposed for election as new Board member and Chairman of the Board. He previously served as CEO of CellaVision from 2015 to 2020. Zlatko has 30 years of industry experience in medical technology, and his previous experience includes serving as CEO of Mölnlycke Healthcare as well as holding senior positions at Gambro, Getinge/Arjo and Cooper Companies. He has Board experience from Etac and Sobi. Since 2026, Zlatko Rihter has also served as Chairman of the Board of Malmö FF, one of Sweden’s leading football clubs. Zlatko holds a Master of Science in Mechanical Engineering from Lund University of Technology and has also studied economics at Lund University.Independence: Zlatko Rihter is independent in relation to the Company, company management, and major shareholders.Shareholding in CellaVision: 70,000 shares. Other InformationThe Nomination Committee’s complete proposals, together with the Nomination Committee’s motivated statement and information regarding the proposed Board members, will be made available on the Company’s website in good time prior to the AGM. The notice convening the AGM is available on the Company’s website.

Contact

Lisa Bodily NordqvistInvestor Relations and Corporate Communications ManagerPhone: + 46 76 345 31 87E-mail: lisa.bodilynordqvist@cellavision.comwww.cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company’s 13 local market support organizations covering more than 40 countries. In 2025, sales were SEK 759 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Attachments

The Nomination Committee’s proposals for the 2026 Annual General Meeting of CellaVision AB